Evidence map›Paper›PMID 33212003›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2021

Oncological outcomes in the management of cT1-T2 cN0 penile squamous cell carcinoma.

Juan Garisto, Madhur Nayan, Kamel Fadaak, Kathy Li, Advait Pandya, Ricardo Leao, Peter Chung, Srikala S Shridar, Joelle Helou, Girish S Kulkarni

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Juan GaristoUniversity of Toronto, Toronto, ON, Canada.
Madhur NayanUniversity of Toronto, Toronto, ON, Canada.
Kamel FadaakUniversity of Toronto, Toronto, ON, Canada.
Kathy LiUniversity of Toronto, Toronto, ON, Canada.
Advait PandyaUniversity of Toronto, Toronto, ON, Canada.
Ricardo LeaoUniversity of Toronto, Toronto, ON, Canada.
Peter ChungUniversity of Toronto, Toronto, ON, Canada.
Srikala S ShridarUniversity of Toronto, Toronto, ON, Canada.
Joelle HelouUniversity of Toronto, Toronto, ON, Canada.
Girish S KulkarniUniversity of Toronto, Toronto, ON, Canada.
University of Toronto · CAPrincess Margaret Cancer Centre · CAUniversity Health Network · CAKing Fahd Hospital of the University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSquamous cell carcinoma (SCC) of the penis is a rare disease comprising 1% of all male cancer. Options for the management of cT1-T2 cN0 penile SCC include partial penectomy (PP), considered the standard, and brachytherapy (BT), which offers acceptable local disease control and organ preservation. The purpose of our study was to assess and describe the oncological outcome for both treatments in a tertiary care center.

methodsWe performed a contemporary retrospective study of patients with early-stage penile cancer treated surgically or by BT at a tertiary center between 2000 and 2016. Demographic, management, and followup data were obtained from an institutional database. Descriptive statistics and survival analysis using Kaplan-Meier plots were calculated. Local and regional recurrences were compared in both groups (BT vs. PP).

resultsA total of 51 patients with cT1-T2N0 penile SCC treated with BT (35) and PP (16) were analyzed. Median followup was 37.1 (13.9-68) and 25.4 months (18-52.3) for the BT and PP groups, respectively. Recurrence developed in seven (20%) patients treated with BT. Median time to recurrence was 35.2 months (range 2.9-95.8). No recurrences were reported in patients treated with PP. Forty-four (86.2%) patients were alive with no evidence of disease at the last followup. Overall survival was 62.7%. Complications after primary tumor treatment were urethral stenosis (15.7%), penile necrosis (7.8%), and local infection (2%).

conclusionsPP provides acceptable local control with organ preservation in early-stage penile SCC. BT was able to offer organ preservation in 69% of men. Future prospective studies are needed to compare other organ-conserving treatment modalities with PP.

Identifiers

PMID33212003
PMCPMC8195575
OpenAlexW3100175331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.